Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | TACR3 | P29371 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14970890 | 0.83 | CYP3A4 (0.78) | CYP3A4MEN1KMT2AMAPTTACR3 | |
| SCHEMBL14970875 | 0.83 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ACYP2C9MAPT | |
| SCHEMBL804472 | 0.81 | CYP3A4 (0.50) | CYP3A4MEN1KMT2ANPC1 | |
| SCHEMBL804704 | 0.81 | KMT2A (0.52) | CYP3A4MEN1KMT2ACYP2C9CYP1A2 | |
| SCHEMBL23722908 | 0.79 | CYP3A4 (1.00) | CYP3A4MEN1KMT2ACYP2C9CYP1A2 | |
| SCHEMBL17689194 | 0.79 | CYP3A4 (0.77) | CYP3A4MEN1KMT2ACYP2C9CYP1A2 | |
| SCHEMBL13253440 | 0.78 | CYP3A4 (0.65) | CYP3A4MEN1KMT2ACYP2C9MAPT | |
| SCHEMBL438393 | 0.78 | DGAT1 (0.63) | CYP3A4MEN1KMT2ACYP2C9CYP1A2 | |
| SCHEMBL28844490 | 0.78 | TACR3 (0.82) | CYP3A4MEN1KMT2ACYP2C9CYP1A2 | |
| SCHEMBL28844487 | 0.78 | TACR3 (0.91) | CYP3A4MEN1KMT2AMAPTTACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040553-B2 | Phenoxyisobutyric acid compounds and method of synthesis | Cell Viable Corporation (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040553-B2 | Phenoxyisobutyric acid compounds and method of synthesis | Cell Viable Corporation (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140350045-A1 | PHENOXYISOBUTYRIC ACID COMPOUNDS AND METHOD OF SYNTHESIS | LALEZARI IRAJ (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350045-A1 | PHENOXYISOBUTYRIC ACID COMPOUNDS AND METHOD OF SYNTHESIS | LALEZARI IRAJ (US) | 2014-11-27 | — | — | US | disclosed |
| US-20120071502-A1 | Novel phenoxyisobutyric acid compounds and methods for synthesis | Cell Viable Corporation (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071502-A1 | Novel phenoxyisobutyric acid compounds and methods for synthesis | Cell Viable Corporation (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350045-A1 | PHENOXYISOBUTYRIC ACID COMPOUNDS AND METHOD OF SYNTHESIS | AGER, BPGM, PDXK | CYP3A4 390/4885MEN1 2478/4885KMT2A 1910/4885 |
| US-20120071502-A1 | Novel phenoxyisobutyric acid compounds and methods for synthesis | AGER, BPGM, PDXK | CYP3A4 1030/4885MEN1 2627/4885KMT2A 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.